Drugs / Immulina TM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05524532 | Jul 2023 → Jul 2025 | post-COVID-19 disorder | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05447078 | Jul 2022 → Dec 2025 | — | University of Mississippi Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immulina TM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05524532 ↗ |
| Modality | Other / unclassified | “a natural dietary supplement” NCT05524532 ↗ |
| Route | Oral | “This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral...” NCT05447078 ↗ |